Nicholas K. Mitrokostas

Nicholas K. Mitrokostas

Nicholas K. Mitrokostas

Nicholas Mitrokostas, a partner in Goodwin’s IP Litigation Group, focuses his practice on intellectual property, with an emphasis on patent litigation and inter partes review proceedings in the Patent Trial and Appeal Board (PTAB). Mr. Mitrokostas has extensive trial and PTAB experience representing clients in the pharmaceutical and biotechnology industries in patent and antitrust litigation. He also has experience counseling and representing higher educational institutions in these matters. In addition to his IP work, Mr. Mitrokostas also served as one of several Goodwin attorneys working on matters related to the criminal investigation and prosecution following the July 2006 Central Artery Tunnel collapse in Boston. Mr. Mitrokostas also devotes significant time to representing pro bono clients in criminal and immigration matters.

Professional Activities

Mr. Mitrokostas is a member of the American Intellectual Property Law Association, IPO, and the Boston, Massachusetts and American Bar Associations, among other organizations.

Professional Experience

From March to September 2008, Mr. Mitrokostas served as a Special Assistant District Attorney for Middlesex County (D. Mass) where he prosecuted more than 200 cases, tried more than 15 jury and non-jury misdemeanor and felony cases, and argued numerous dispositive and evidentiary motions.

Mr. Mitrokostas has served as an adjunct professor teaching Patent Law at Northeastern University School of Law and has guest-lectured in other courses.


Mr. Mitrokostas has been named a Super Lawyers’ Rising Star for 2011-2015. During law school, Mr. Mitrokostas served as Editor in Chief of Law & Policy in International Business (renamed Georgetown Journal of International Law).

Areas of Practice


Some of Mr. Mitrokostas’ recent representations include:

  • Teva Pharmaceuticals, Inc. v. Sandoz, Inc.: Representing Teva Pharmaceuticals in a significant patent litigation involving Teva’s blockbuster branded product, Copaxone®, the most prescribed treatment for relapsing forms of multiple sclerosis. The court ruled that Teva’s nine patents were valid, enforceable and infringed by the defendants’ ANDAs, which was partially upheld on appeal. The case was heard by the U.S. Supreme Court and in January 2015, the Court delivered a precedent-setting decision in favor of Teva.
  • Coalition for Affordable Drugs VIII, LLC v. The Trustees of the University of Pennsylvania: Representing patent owner the Trustees of the University of Pennsylvania in an inter partes review proceeding involving patents directed to the treatment of hypercholesterolemia and hyperlipidemia with a novel dosing regimen for the drug lomitapide. The case is pending in the PTAB.
  • Mylan Pharmaceuticals, Inc. v. Yeda Research and Development:  Representing patent owner Yeda Research and Development in an inter partes review proceeding involving patents directed to the treatment of multiple sclerosis with a novel dosing regimen for the drug glatiramer acetate.
  • Teva Branded Pharmaceutical Products R&D, Inc. v. Perrigo, Inc.: Represented Teva Branded Pharmaceutical Products R&D, Inc. in patent litigation involving its inhaler, ProAir® HFA, the most widely prescribed albuterol sulfate metered-dose inhaler. The case was settled favorably.
  • In re Bendamustine Consolidated Litigation: Representing Cephalon, Inc. in patent litigation against 18 defendants involving Cephalon’s branded cancer drug, Treanda®, which is indicated for the treatment of certain lymphomas. The U.S. District Court for the District of Delaware (Judge Gregory M. Sleet) issued a final decision in favor of Cephalon, upholding the validity and finding infringement of all patents-in-suit following a six-day bench trial. The case is now on appeal.
  • Valeant et al. v. Mylan Phamaceuticals, Inc. et al.:  Representing ANDA-filer Actavis LLC in patent litigation involving injectable methylnaltrexone products.  The case is pending in the U.S. District Court for the District of New Jersey.
  • Mass. Inst. Tech. v. Shire: Representing M.I.T. in litigation involving infringement of patents relating to novel cellular-scaffolds discovered by Professors Bob Langer and Jay Vacanti. The action is pending in the U.S. District Court for the District of Massachusetts.
  • Teva Pharmaceuticals USA, Inc. v. Pfizer, Inc.: Represented Teva Pharmaceuticals USA as ANDA-defendant in patent litigation involving Pfizer’s products, Detrol® and Detrol® LA. The case was settled favorably.
  • Cephalon, Inc. v. Celgene, Corp.: Represented Cephalon, Inc. in patent infringement litigation involving a paclitaxel drug formulation in the U.S. District Court for the District of Massachusetts.
  • Genzyme, Inc. v. Anika Therapeutics, Inc.: Represented medical device company, Anika Therapeutics, Inc., which was sued for patent infringement relating to its proposed hyaluronic acid injection therapy, Monovisc®, in the U.S. District Court for the District of Massachusetts.



J.D., 2003
Georgetown University Law Center

(magna cum laude, Order of the Coif)

A.B., 1999
Harvard College

(magna cum laude)


2003 to 2004 Massachusetts Supreme Judicial Court, Honorable Judith A. Cowin



New York


U.S. District Court for the District of Massachusetts
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers